Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Anticancer Res

Retrieve available abstracts of 96 articles:
HTML format

Single Articles

    August 2022
  1. YOTSUMOTO F, Sanui A, Ito T, Miyahara D, et al
    Cumulative Summation Analysis of Learning Curve for Robotic-assisted Hysterectomy in Patients With Gynecologic Tumors.
    Anticancer Res. 2022;42:4111-4117.
    PubMed     Abstract available

  2. OGATA N, Toh U, Sudou T, Ogata S, et al
    Efficacy and Safety of Monthly Minodronate Therapy in Postmenopausal Breast Cancer Patients Receiving Aromatase Inhibitors.
    Anticancer Res. 2022;42:4139-4143.
    PubMed     Abstract available

  3. YOKOYAMA Y, Kubo-Kaneda M, Sunada K, Teishikata Y, et al
    Adverse Events Associated With Long-term Treatment of Epithelial Ovarian Cancer With Bevacizumab and Chemotherapy.
    Anticancer Res. 2022;42:4165-4171.
    PubMed     Abstract available

    July 2022
  4. VEYSSIERE H, Aldarazi G, Molnar I, Durando X, et al
    Nestin as a Prognostic Biomarker in High-grade Epithelial Ovarian Cancer Treated by Neoadjuvant Chemotherapy.
    Anticancer Res. 2022;42:3583-3594.
    PubMed     Abstract available

  5. RAJHA A, Piso P, Halmy L, Panczel I, et al
    Rare Histologies and Infrequent Indications for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Anticancer Res. 2022;42:3681-3692.
    PubMed     Abstract available

  6. IMAMURA A, Oike T, Sato H, Yoshimoto Y, et al
    Comparative Analysis of the Antitumor Immune Profiles of Paired Radiotherapy-naive and Radiotherapy-treated Cervical Cancer Tissues.
    Anticancer Res. 2022;42:3341-3348.
    PubMed     Abstract available

  7. TATE S, Nishikimi K, Matsuoka A, Otsuka S, et al
    Highly Aggressive Surgery Benefits in Patients With Advanced Ovarian Cancer.
    Anticancer Res. 2022;42:3707-3716.
    PubMed     Abstract available

    June 2022
  8. GIVENS NT, Zhao L, Zhu Z, Lequio M, et al
    Mangosteen Inhibits Growth and Survival of Cervical Cancer Cells.
    Anticancer Res. 2022;42:2903-2909.
    PubMed     Abstract available

  9. UNO A, Yamamoto S, Iihara H, Fujii H, et al
    Control and Risk Factors of Nausea and Vomiting in Patients With Cervical Cancer Receiving Radiotherapy.
    Anticancer Res. 2022;42:3117-3123.
    PubMed     Abstract available

  10. OOYAMA T, Shimoji Y, Nakasone T, Arakaki Y, et al
    Effects of Pegylated Liposomal Doxorubicin and CA125 Level Variability Analysis in Platinum-refractory/resistant Recurrent Ovarian Cancer.
    Anticancer Res. 2022;42:3017-3022.
    PubMed     Abstract available

    May 2022
  11. TATE S, Nishikimi K, Matsuoka A, Otsuka S, et al
    Bevacizumab-based Salvage Chemotherapy Improves Survival Outcomes for Patients With Brain Metastasis from Ovarian Cancer.
    Anticancer Res. 2022;42:2637-2644.
    PubMed     Abstract available

  12. ASP M, Malander S, Bengtsson J, Sartor H, et al
    Prognostic Value of Peritoneal Cancer Index After Complete Cytoreductive Surgery in Advanced Ovarian Cancer.
    Anticancer Res. 2022;42:2541-2551.
    PubMed     Abstract available

  13. MAGKANA M, Mentzelopoulou P, Magkana E, Pampanos A, et al
    p16/Ki-67 Dual Staining Is a Reliable Biomarker for Risk Stratification for Patients With Borderline/Mild Cytology in Cervical Cancer Screening.
    Anticancer Res. 2022;42:2599-2606.
    PubMed     Abstract available

    April 2022
  14. AN J, Oh HE, Kim H, Lee JH, et al
    Significance of Altered Fatty Acid Transporter Expressions in Uterine Cervical Cancer and Its Precursor Lesions.
    Anticancer Res. 2022;42:2131-2137.
    PubMed     Abstract available

  15. GADDUCCI A, Cosio S, Landoni F, Lissoni AA, et al
    Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study.
    Anticancer Res. 2022;42:2017-2022.
    PubMed     Abstract available

  16. MITSOPOULOS V, Innamaa A, Lippiatt J, Collins S, et al
    Differences in Patterns of Recurrence Between Primary and Interval Debulking Surgery for Advanced Ovarian Cancer.
    Anticancer Res. 2022;42:2003-2008.
    PubMed     Abstract available

  17. ADDLEY S, McGowan M, Asher V, Bali A, et al
    Lactate Is a Reliable Predictor of ICU Length of Stay Following Ultra-radical Ovarian Cancer Surgery.
    Anticancer Res. 2022;42:1979-1986.
    PubMed     Abstract available

  18. SHORAKA M, Carbajal-Mamani SL, Dideban B, Zarrinpar A, et al
    Clinical Utility and Cost of Postoperative Hemoglobin Level Testing Following Robotic-assisted Hysterectomy for Endometrial Cancer.
    Anticancer Res. 2022;42:1893-1898.
    PubMed     Abstract available

  19. ABOBAKER S, Kulbe H, Taube ET, Darb-Esfahani S, et al
    Polycomb Protein BMI-1 as a Potential Therapeutic Target in Mucinous Ovarian Cancer.
    Anticancer Res. 2022;42:1739-1747.
    PubMed     Abstract available

  20. OHASHI K, Li TS, Miura S, Hasegawa Y, et al
    Biological Differences Between Ovarian Cancer-associated Fibroblasts and Contralateral Normal Ovary-derived Mesenchymal Stem Cells.
    Anticancer Res. 2022;42:1729-1737.
    PubMed     Abstract available

    March 2022
  21. HECKING T, Thiesler T, Halbe J, Otten L, et al
    Programmed Cell Death Ligand-1 (PDL-1) Correlates With Tumor Infiltration by Immune Cells and Represents a Promising Target for Immunotherapy in Endometrial Cancer.
    Anticancer Res. 2022;42:1367-1376.
    PubMed     Abstract available

    February 2022
  22. DELRUE C, Vanwalleghem L, Paepe P, Trappen PV, et al
    Stratified Mucin-producing Intraepithelial Lesions of the Cervix: Clinical Diversity of Cases and Literature Review.
    Anticancer Res. 2022;42:1175-1180.
    PubMed     Abstract available

  23. MATSUDA R, Sato F, Kotsugi M, Morimoto T, et al
    Awake Surgery for Local Recurrence of Brain Metastasis in the Precentral Gyrus After Fractionated Stereotactic Radiotherapy: A Technical Case Report.
    Anticancer Res. 2022;42:1151-1155.
    PubMed     Abstract available

  24. SHIBATA N, Kawakami K, Hisanori S, Kobayashi K, et al
    Investigation of Hypersensitivity Reactions in Carboplatin Desensitization Therapy.
    Anticancer Res. 2022;42:1091-1097.
    PubMed     Abstract available

  25. ALEXOPOULOS A, Karanikiotis C, Ardavanis A, Boukovinas I, et al
    Safety and Efficacy of RAD001 (Everolimus) Administered Upon Relapse During or After Adjuvant Treatment in Post-menopausal Women With Hormone Receptor Positive, HER2/neu Negative Locally Advanced or Metastatic Breast Cancer (CRAD001JGR08 "MELPOMENI" s
    Anticancer Res. 2022;42:1031-1041.
    PubMed     Abstract available

  26. DOBILAS A, Thalin C, Wallen H, Borgfeldt C, et al
    Circulating Markers of Neutrophil Extracellular Traps (NETs) in Patients With Ovarian Tumors.
    Anticancer Res. 2022;42:965-971.
    PubMed     Abstract available

  27. GADDUCCI A, Simonetti E, Mezzapesa F, Cosio S, et al
    Computed Tomography-assessed Skeletal Muscle Index and Skeletal Muscle Radiation Attenuation in Patients With Ovarian Cancer Treated With Primary Surgery Followed by Platinum-based Chemotherapy: A Single-center Italian Study.
    Anticancer Res. 2022;42:947-954.
    PubMed     Abstract available

    January 2022
  28. HOSOYA S, Ueda K, Odajima S, Ogawa K, et al
    Scoring Systems of Peritoneal Dissemination for the Prediction of Operative Completeness in Advanced Ovarian Cancer.
    Anticancer Res. 2022;42:115-124.
    PubMed     Abstract available

  29. CARDENAS-GOICOECHEA J, Wang YU, Lee JH, Shoraka M, et al
    Survival After Minimally Invasive Surgery in Older Women With Endometrial Carcinoma.
    Anticancer Res. 2022;42:75-85.
    PubMed     Abstract available

  30. ACS M, Piso P, Prader S
    Current Status of Metastatic Cardiophrenic Lymph Nodes (CPLNs) in Patients With Ovarian Cancer: A Review.
    Anticancer Res. 2022;42:13-24.
    PubMed     Abstract available

  31. BISKUP E, Wils RS, Hogdall C, Hogdall E, et al
    Prospects of Improving Early Ovarian Cancer Diagnosis Using Cervical Cell Swabs.
    Anticancer Res. 2022;42:1-12.
    PubMed     Abstract available

  32. LEE J, Kim JM, Lee YH, Chong GO, et al
    Correlation Between Clinical Outcomes and Serum CA-125 Levels After Standard Treatment for Epithelial Ovarian Cancer.
    Anticancer Res. 2022;42:349-353.
    PubMed     Abstract available

  33. LEE EJ, Park SJ, Lee J, Mun J, et al
    The Clinical Desire for Pressurized Intraperitoneal Aerosol Chemotherapy in South Korea: An Electronic Survey-based Study.
    Anticancer Res. 2022;42:363-371.
    PubMed     Abstract available

    December 2021
  34. LEE J, Kim JM, Lee YH, Chong GO, et al
    Applicability of the Histoculture Drug Response Assay to Predict Platinum Sensitivity and Prognosis in Ovarian Cancer.
    Anticancer Res. 2021;41:6287-6292.
    PubMed     Abstract available

  35. CHECK JH, Check D
    New Insights as to Why Progesterone Receptor Modulators, such as Mifepristone, Seem to Be More Effective in Treating Cancers that Are Devoid of the Classical Nuclear Progesterone Receptor.
    Anticancer Res. 2021;41:5873-5880.
    PubMed     Abstract available

    November 2021
  36. ISONO R, Tsubamoto H, Ueda T, Takimoto Y, et al
    Itraconazole Inhibits Intracellular Cholesterol Trafficking and Decreases Phosphatidylserine Level in Cervical Cancer Cells.
    Anticancer Res. 2021;41:5477-5480.
    PubMed     Abstract available

    October 2021
  37. NOSAKA K, Suzuki S, Yoshikawa T, Shimomura M, et al
    Heat Shock Protein 105 as an Immunotherapeutic Target for Patients With Cervical Cancer.
    Anticancer Res. 2021;41:4741-4751.
    PubMed     Abstract available

  38. GADDUCCI A, Cosio S
    Randomized Clinical Trials and Real World Prospective Observational Studies on Bevacizumab, PARP Inhibitors, and Immune Checkpoint Inhibitors in the First-Line Treatment of Advanced Ovarian Carcinoma: A Critical Review.
    Anticancer Res. 2021;41:4673-4685.
    PubMed     Abstract available

  39. LUENGAS-WUERZINGER V, Rawert F, CLAssEN-VON Spee S, Baransi S, et al
    Role of the Cardiophrenic Lymph Node Status After Neoadjuvant Chemotherapy in Primary Advanced Ovarian Cancer.
    Anticancer Res. 2021;41:5025-5031.
    PubMed     Abstract available

    September 2021
  40. SHIN W, Noh JJ, Baek SH, Kim BG, et al
    Real-world Experience of Niraparib in Newly-diagnosed Epithelial Ovarian Cancer.
    Anticancer Res. 2021;41:4603-4607.
    PubMed     Abstract available

  41. CHOI KH, Kim H, Bae GE, Lee SH, et al
    Mesonephric-like Differentiation of Ovarian Endometrioid and High-grade Serous Carcinomas: Clinicopathological and Molecular Characteristics Distinct from Those of Mesonephric-like Adenocarcinoma.
    Anticancer Res. 2021;41:4587-4601.
    PubMed     Abstract available

  42. GADDUCCI A, Ugolini C, Cosio S, Vistoli F, et al
    Primary Perivascular Epithelioid Cell Tumor (PEComa) of the Ovary: A Case Report and Review of the Literature.
    Anticancer Res. 2021;41:4483-4488.
    PubMed     Abstract available

  43. LAI J, Tong C, Chien JR
    Ovarian Serous Carcinoma With a Novel HSP90AB1 Mutation in a Patient With Synchronous Primary Fallopian Tube Serous Carcinoma.
    Anticancer Res. 2021;41:4417-4422.
    PubMed     Abstract available

  44. RADES D, Kopelke S, Soror T, Schild SE, et al
    Sleep Disorders Prior to Adjuvant Radiation Therapy for Gynecological Malignancies.
    Anticancer Res. 2021;41:4407-4410.
    PubMed     Abstract available

  45. MIYAKE R, Yamanaka S, Matsubara S, Mabuchi S, et al
    Preclinical Activity of Plitidepsin Against Clear Cell Carcinoma of the Ovary.
    Anticancer Res. 2021;41:4277-4285.
    PubMed     Abstract available

  46. ISONO R, Tsubamoto H, Inoue K, Ueda T, et al
    Itraconazole Increases Resolvin E3 Concentration and 12/15-lipoxygenase Inhibitor Attenuates Itraconazole Cytotoxicity in Cervical Cancer Cells.
    Anticancer Res. 2021;41:4271-4276.
    PubMed     Abstract available

  47. CARUSO G, Palaia I, DI Donato V, Pernazza A, et al
    Radical Surgery After Neoadjuvant Chemotherapy for Locally Advanced Neuroendocrine Cancer of the Cervix.
    Anticancer Res. 2021;41:4431-4438.
    PubMed     Abstract available

    August 2021
  48. AKAZAWA M, Hashimoto K, Lee SL, Liu WM, et al
    Learning Curve of Robotic-assisted Hysterectomy With Pelvic Lymphadenectomy for Early Stage Endometrial Cancer: Analysis of 81 Cases.
    Anticancer Res. 2021;41:4173-4178.
    PubMed     Abstract available

  49. YOSHIDA K, Kondo E, Nimura R, Maki S, et al
    Laparoscopic Versus Robotic Hysterectomy in Obese Patients With Early-stage Endometrial Cancer: A Single-centre Analysis.
    Anticancer Res. 2021;41:4163-4167.
    PubMed     Abstract available

  50. KONDO E, Nimura R, Maki S, Kaneda M, et al
    Prognostic Benefit of >/=6 Cycles of Neoadjuvant Chemotherapy for Advanced Ovarian, Tubal, and Peritoneal Cancers.
    Anticancer Res. 2021;41:4157-4161.
    PubMed     Abstract available

  51. KUBO-KANEDA M, Kondo E, Nimura R, Maki S, et al
    Effectiveness of Laparoscopic Combined Retroperitoneal and Transperitoneal Approach in Para-aortic Lymphadenectomy for Endometrial Cancer.
    Anticancer Res. 2021;41:4151-4155.
    PubMed     Abstract available

  52. TAMURA D, Maeda D, Enomoto K, Sato H, et al
    Severe Abdominal Recurrence of Low-grade Endometrial Stromal Sarcoma After Hysteroscopic Surgery.
    Anticancer Res. 2021;41:4013-4016.
    PubMed     Abstract available

    July 2021
  53. MIRANDA A, Jurgensen C, Chekerov R, Chopra S, et al
    EUS-guided Transgastric Drainage to Manage a Postoperative Pancreatic Fistula After Distal Pancreatectomy and Splenectomy in Recurrent Ovarian Cancer: A Case Report.
    Anticancer Res. 2021;41:3649-3656.
    PubMed     Abstract available

  54. KIESEL M, Sauer S, Lob S, Herbert SL, et al
    Total Mesometrial Resection With (Neo)Adjuvant Chemotherapy in Locally Advanced Cervical Cancer: A Tumor Response Score.
    Anticancer Res. 2021;41:3543-3560.
    PubMed     Abstract available

  55. SHAM N, Qin C, Zhu Z, Redington CG, et al
    Raspberry Extract With Potential Antitumor Activity Against Cervical Cancer.
    Anticancer Res. 2021;41:3343-3348.
    PubMed     Abstract available

  56. FRIEDRICH M, Friedrich D, Kraft C, Rogmans C, et al
    Multimodal Treatment of Primary Advanced Ovarian Cancer.
    Anticancer Res. 2021;41:3253-3260.
    PubMed     Abstract available

    June 2021
  57. COLLINS A, Spooner S, Horne J, Chainrai M, et al
    Peri-operative Variables Associated With Prolonged Intensive Care Stay Following Cytoreductive Surgery for Ovarian Cancer.
    Anticancer Res. 2021;41:3059-3065.
    PubMed     Abstract available

  58. EGGER EK, Liesenfeld H, Stope MB, Recker F, et al
    Pelvic Exenteration in Advanced Gynecologic Malignancies - Who Will Benefit?
    Anticancer Res. 2021;41:3037-3043.
    PubMed     Abstract available

  59. WATANABE K, Hayashi T, Katsumata M, Sano K, et al
    Development of Uterine Leiomyosarcoma During Follow-up After Caesarean Section in a Woman With Uterine Leiomyoma.
    Anticancer Res. 2021;41:3001-3010.
    PubMed     Abstract available

  60. KIM JH, Park WH, Suh DH, Kim K, et al
    Calcitriol Combined With Platinum-based Chemotherapy Suppresses Growth and Expression of Vascular Endothelial Growth Factor of SKOV-3 Ovarian Cancer Cells.
    Anticancer Res. 2021;41:2945-2952.
    PubMed     Abstract available

    May 2021
  61. CHOI S, Na K, Kim SW, Kim HS, et al
    Dedifferentiated Mesonephric-like Adenocarcinoma of the Uterine Corpus.
    Anticancer Res. 2021;41:2719-2726.
    PubMed     Abstract available

  62. ZHANG R, Wang T, Lin J
    Synergistic Effect of Bazedoxifene and PARP Inhibitor in the Treatment of Ovarian Cancer Regardless of BRCA Mutation.
    Anticancer Res. 2021;41:2277-2286.
    PubMed     Abstract available

    April 2021
  63. CHECK JH, Check D, Poretta T, Wilson C, et al
    Palliative Benefits of Oral Mifepristone for the Treatment of Metastatic Fibroblastic Osteosarcoma.
    Anticancer Res. 2021;41:2111-2115.
    PubMed     Abstract available

  64. NASSER S, Fotopoulou C, Richter R, Kaulich J, et al
    Prognostic Value and Therapeutic Implications of Pleural Carcinosis and Malignant Pleural Effusion in Advanced Epithelial Ovarian Cancer.
    Anticancer Res. 2021;41:2033-2038.
    PubMed     Abstract available

  65. GADDUCCI A, Simonetti E, Guidoccio F, Manca G, et al
    Have Volume-based Parameters of Positron Emission Tomography/Computed Tomography Prognostic Relevance for Patients With Potentially Platinum-responsive Recurrent Ovarian Cancer? A Single Center Italian Study.
    Anticancer Res. 2021;41:1937-1944.
    PubMed     Abstract available

  66. PANAGOPOULOS I, Andersen K, Ramslien LF, Ikonomou IM, et al
    Therapy-related Myeloid Leukemia With the Translocation t(8;19)(p11;q13) Leading to a KAT6A-LEUTX Fusion Gene.
    Anticancer Res. 2021;41:1753-1760.
    PubMed     Abstract available

    March 2021
  67. YANO M, Miyazawa M, Ogane N, Ogasawara A, et al
    Up-regulation of HDAC6 Results in Poor Prognosis and Chemoresistance in Patients With Advanced Ovarian High-grade Serous Carcinoma.
    Anticancer Res. 2021;41:1647-1654.
    PubMed     Abstract available

  68. KWON HJ, Song SY, Kim HS
    Prominent Papillary Growth Pattern and Severe Nuclear Pleomorphism Induced by Neoadjuvant Chemotherapy in Ovarian Mucinous Carcinoma: Potential for Misdiagnosis as High-grade Serous Carcinoma.
    Anticancer Res. 2021;41:1579-1586.
    PubMed     Abstract available

  69. MEYER HJ, Wienke A, Surov A
    Pre-treatment Apparent Diffusion Coefficient Does Not Predict Therapy Response to Radiochemotherapy in Cervical Cancer: A Systematic Review and Meta-analysis.
    Anticancer Res. 2021;41:1163-1170.
    PubMed     Abstract available

  70. KAYACAN S, Yilancioglu K, Akdemir AS, Kaya-Dagistanli F, et al
    Synergistic Effect of Apigenin and Curcumin on Apoptosis, Paraptosis and Autophagy-related Cell Death in HeLa Cells.
    Anticancer Res. 2021;41:1271-1282.
    PubMed     Abstract available

    February 2021
  71. MIYAMOTO M, Hada T, Ishibashi H, Iwahashi H, et al
    A New Model to Improve the Prediction of Prognosis of Endometrial Carcinoma by Combining Traditional Classification With the Presence of Tumor-infiltrating Lymphocytes.
    Anticancer Res. 2021;41:1047-1053.
    PubMed     Abstract available

  72. JOCHUM F, Aubry G, Pellerin M, Billard C, et al
    Relevance of Laparoscopic Surgery for Ovarian Cancer in Well-selected Patients: A Propensity-matched Comparison With Laparotomy.
    Anticancer Res. 2021;41:955-965.
    PubMed     Abstract available

  73. MANDATO VD, Torricelli F, Mastrofilippo V, Pirillo D, et al
    Impact of a Province-wide Endometrial Cancer Guideline on Daily Practice.
    Anticancer Res. 2021;41:937-948.
    PubMed     Abstract available

  74. URPILAINEN E, Arima R, Karihtala P, Puistola U, et al
    Metformin Associates With Aggressive Features of Endometrial Cancer in Women With Type 2 Diabetes.
    Anticancer Res. 2021;41:821-828.
    PubMed     Abstract available

  75. KIM HJ, Heo K
    YYB-101, a Humanized Antihepatocyte Growth Factor Monoclonal Antibody, Inhibits Ovarian Cancer Cell Motility and Proliferation.
    Anticancer Res. 2021;41:671-678.
    PubMed     Abstract available

  76. EGGER EK, Stope MB, Recker F, Konsgen D, et al
    Lower Genital Tract Melanomas: Staging, Predictors of Outcome, and New Therapeutic Options.
    Anticancer Res. 2021;41:999-1004.
    PubMed     Abstract available

    January 2021
  77. DI MARTINO G, Lissoni AA, Ferrari D, DI Meo ML, et al
    Dose-dense Neoadjuvant Chemotherapy With Paclitaxel and Carboplatin in Cervical Cancer: Efficacy on Pathological Response.
    Anticancer Res. 2021;41:497-502.
    PubMed     Abstract available

  78. SHIMIZU Y, Suzuki S, Ukai M, Hattori S, et al
    The Prognostic Significance of Peritumoral Lymphocytes' Band-like Structure in Type II Endometrial Cancer.
    Anticancer Res. 2021;41:249-258.
    PubMed     Abstract available

  79. GADDUCCI A, Cosio S
    The Prognostic Relevance of Computed Tomography-assessed Skeletal Muscle Index and Skeletal Muscle Radiation Attenuation in Patients With Gynecological Cancer.
    Anticancer Res. 2021;41:9-20.
    PubMed     Abstract available

    December 2020
  80. CHECK JH, Check D, Srivastava MD, Poretta T, et al
    Treatment With Mifepristone Allows a Patient With End-stage Pancreatic Cancer in Hospice on a Morphine Drip to Restore a Decent Quality of Life.
    Anticancer Res. 2020;40:6997-7001.
    PubMed     Abstract available

  81. SOPO M, Anttila M, Muukkonen OT, YlA-Herttuala S, et al
    Microvessels in Epithelial Ovarian Tumors: High Microvessel Density Is a Significant Feature of Malignant Ovarian Tumors.
    Anticancer Res. 2020;40:6923-6931.
    PubMed     Abstract available

  82. LU KW, Yang MD, Peng SF, Chen JC, et al
    Maslinic Acid Induces DNA Damage and Impairs DNA Repair in Human Cervical Cancer HeLa Cells.
    Anticancer Res. 2020;40:6869-6877.
    PubMed     Abstract available

  83. MIYAZAWA M, Yasuda M, Miyazawa M, Ogane N, et al
    Hypoxia-inducible Factor-1alpha Suppression in Ovarian Clear-cell Carcinoma Cells by Silibinin Administration.
    Anticancer Res. 2020;40:6791-6798.
    PubMed     Abstract available

  84. DE BREE E, Katsougkri D, Polioudaki H, Tsangaridou E, et al
    Hyperthermia During Intraperitoneal Chemotherapy With Paclitaxel or Docetaxel for Ovarian Cancer: Is There Any Benefit?
    Anticancer Res. 2020;40:6769-6780.
    PubMed     Abstract available

  85. FILIPPOV-LEVY N, Davidson B, Reich R
    The Biological Role of the Long Non-coding RNA LINK-A in Ovarian Carcinoma.
    Anticancer Res. 2020;40:6677-6684.
    PubMed     Abstract available

  86. GULIYEVA G, Huayllani MT, Avila FR, Boczar D, et al
    Younger Age as a Risk Factor for Gynecologic Cancer-related Lymphedema: A Systematic Review.
    Anticancer Res. 2020;40:6609-6612.
    PubMed     Abstract available

    November 2020
  87. LEE S, Jun J, Kim WJ, Tamayo P, et al
    WNT Signaling Driven by R-spondin 1 and LGR6 in High-grade Serous Ovarian Cancer.
    Anticancer Res. 2020;40:6017-6028.
    PubMed     Abstract available

  88. HUFFMAN D, Wegner R, Jalil A, Krivak T, et al
    Survival After Primary Surgery Compared With Neoadjuvant Chemotherapy in Early-stage Ovarian Cancer.
    Anticancer Res. 2020;40:6003-6008.
    PubMed     Abstract available

  89. GADDUCCI A, Cosio S, Fruzzetti F
    Estro-progestin Contraceptives and Risk of Cervical Cancer: A Debated Issue.
    Anticancer Res. 2020;40:5995-6002.
    PubMed     Abstract available

    October 2020
  90. MITSOPOULOS V, Innamaa A, Lippiatt J, Plevris N, et al
    Radical Surgical Procedures in Advanced Ovarian Cancer and Differences Between Primary and Interval Debulking Surgery.
    Anticancer Res. 2020;40:5869-5875.
    PubMed     Abstract available

  91. CHINCZEWSKI L, Taube ET, Feldhaus FW, DrOge LA, et al
    Angiosarcomas of Primary Gynecologic Origin - A Case Series and Review of the Literature.
    Anticancer Res. 2020;40:5743-5750.
    PubMed     Abstract available

  92. MINAGAWA Y, Ishino K, Wada R, Kudo M, et al
    High Expression of p21 as a Potential Therapeutic Target in Ovarian Clear-cell Carcinoma.
    Anticancer Res. 2020;40:5631-5639.
    PubMed     Abstract available

  93. OH CK, Park JJ, Ha M, Heo HJ, et al
    LRRC17 Is Linked to Prognosis of Ovarian Cancer Through a p53-dependent Anti-apoptotic Function.
    Anticancer Res. 2020;40:5601-5609.
    PubMed     Abstract available

  94. HSIEH Y, Tseng JJ
    Azidothymidine (AZT) Inhibits Proliferation of Human Ovarian Cancer Cells by Regulating Cell Cycle Progression.
    Anticancer Res. 2020;40:5517-5527.
    PubMed     Abstract available

  95. YOSHINO AI, Kobayashi E, Kodama M, Hashimoto K, et al
    Oncological and Reproductive Outcomes of Abdominal Radical Trachelectomy.
    Anticancer Res. 2020;40:5939-5947.
    PubMed     Abstract available

  96. SHIBA S, Wakatsuki M, Ohno T, Nakano T, et al
    Differences in Linear Energy Transfer Affect Cell-killing and Radiosensitizing Effects of Spread-out Carbon-ion Beams.
    Anticancer Res. 2020;40:5497-5502.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.